The role of mechanical support devices during percutaneous coronary intervention

Ritesh Kanyal and Jonathan Byrne

Abstract
The practice of interventional cardiology has changed dramatically over the last four decades since Andreas Gruentzig carried out the first balloon angioplasty. The obvious technological improvements in stent design and interventional techniques have facilitated the routine treatment of a higher risk cohort of patients, including those with complex coronary artery disease and poor left ventricular function, and more often in the setting of cardiogenic shock (CS) complicating acute myocardial infarction (AMI). The use of mechanical cardiac support (MCS) in these settings has been the subject of intense interest, particularly over the past decade. A number of commercially available devices now add to the interventional cardiologist's armamentarium when faced with the critically unwell or high-risk patient in the cardiac catheter laboratory. The theoretical advantage of such devices in these settings is clear: an increase in cardiac output and hence mean arterial pressure, with variable effects on coronary blood flow. In doing so, they have the potential to prevent the downward cascade of ischaemia and hypoperfusion, but there is a paucity of evidence to support their routine use in any patient subset, even those presenting with cardiogenic shock. This review will discuss the use and haemodynamic effect of MCS devices during percutaneous coronary intervention (PCI), and also examine the clinical evidence for their use in patients with cardiogenic shock, and those undergoing 'high risk' PCI.

Keywords
PCI, IABP, ECMO, CS, high risk patient

Introduction
The practice of interventional cardiology has changed dramatically over the four decades since Andreas Gruentzig carried out the first balloon angioplasty. The obvious technological improvements in stent design and interventional techniques have facilitated the routine treatment of a higher risk cohort of patients, including those with complex coronary artery disease and poor left ventricular function, and more often in the setting of cardiogenic shock (CS) complicating acute myocardial infarction (AMI). The use of mechanical cardiac support (MCS) in these settings has been the subject of intense interest, particularly over the past decade. A number of commercially available devices now add to the interventional cardiologist's armamentarium when faced with the critically unwell or high-risk patient in the cardiac catheter laboratory. The theoretical advantage of such devices in these settings is clear: an increase in cardiac output and hence mean arterial pressure, with variable effects on coronary blood flow. In doing so, they have the potential to prevent the downward cascade of ischaemia and hypoperfusion, but there is a paucity of evidence to support their routine use in any patient subset, even those presenting with cardiogenic shock. This review will discuss the use and haemodynamic effect of MCS devices during percutaneous coronary intervention (PCI), and also examine the clinical evidence for their use in patients with cardiogenic shock, and those undergoing 'high risk' PCI.
use in patients with cardiogenic shock, and those undergoing ‘high risk’ PCI.

**Theoretical principles of mechanical support**

In severe LV systolic dysfunction, myocardial contractility and stroke volume are reduced whilst LV end diastolic volume/pressure (LVEDV/P) is increased leading to decreased cardiac output (CO) and end organ hypoperfusion. In normal physiological circumstance stroke volume/work and myocardial oxygen demand are determined by preload, myocardial contractility and afterload. At cardiac level preload is most often taken to be LVEDP or LAP (Left atrial pressure) while after load is wall stress, in turn defined as LV pressure x cavity radius/wall thickness.8

In CS complicating AMI the left ventricle (LV) is unable to effectively unload leading to an increased LVEDP, low CO, increased wall stress and stroke work, decreased myocardial perfusion, end organ perfusion and increased myocardial oxygen demand thus creating a downward spiral of haemodynamic compromise, systemic inflammatory response and worsening myocardial ischaemia.9 Though many clinical factors (age at presentation, time to reperfusion, infarct size, delayed presentation, out of hospital cardiac arrest, adequacy of revascularisation) are associated with outcomes in AMI, multiple studies have identified the haemodynamic parameter of cardiac power output (CPO) defined as cardiac output x mean arterial pressure/451, <0.6 watt to be an important predictor for in hospital mortality in patients admitted with CS8,10,11

In patients with a large ischaemic burden and poor LV function undergoing PCI, further ischaemia can lead to a further reduction in contractility of an already depressed ventricle and trigger a circulatory collapse. Therefore, MCS has the potential haemodynamic effect of unloading the LV, decreasing LVEDP/LVEDV, stroke work, increasing cardiac output and thereby improving systemic and coronary perfusion.

**Available percutaneous support devices**

Currently available percutaneous MCS devices are shown in Figure 1, with a comparison of their mechanism, haemodynamics and procedural aspects of implantation in Table 1. The ideal MCS device is able to provide haemodynamic support to maintain adequate systemic perfusion, improve mean arterial pressure, and decrease myocardial oxygen demand by a concomitant reduction in left ventricular pre and after load, whilst maintaining, or increasing coronary perfusion.

**The intra-aortic balloon pump (IABP)**

The intra-aortic balloon pump (IABP) was introduced into clinical practice in 1968 and remains the most widely used percutaneous MCS, due to availability and ease of insertion.12 The device is usually inserted via the femoral artery, although the axillary, brachial and iliac routes have also been successfully used. The distal end of device is positioned retrogradely, 2–3 cm distal to left subclavian artery at the level of carina. Balloon inflation is with helium, used due to its low viscosity that facilitates easy transfer in and out of the balloon in addition to its rapid absorption in blood in case of balloon rupture. The IABP counter pulsation mechanism is triggered by invasive arterial pressure or the electrocardiogram. The balloon is fully inflated at onset of diastole after closure of the aortic valve with deflation before opening. Given that most coronary blood flow occurs in diastole, counterpulsation therefore augments coronary perfusion when microcirculatory autoregulation has been exhausted in stenosed coronary arteries as well as reducing afterload and cardiac work.13

The device is simple to use and has a very low profile compared to other devices, but the degree of

---

**Figure 1. Percutaneous LV support options available.**
haemodynamic support generated is modest. The precise augmentation of cardiac output will vary, and requires cardiac synchrony, optimal balloon position, sizing and timing of balloon inflation in diastole and deflation in systole. The MEGA IABP (50 cc balloon) can provide a greater haemodynamic support compared to a standard size IABP with no increase in vascular complication rate. The IABP can be used without a need for anticoagulation if risk of bleeding is high with no increment in rate of limb ischaemia or thromboembolism. Severe aortic regurgitation (AR) is an absolute contraindication to use of device and caution should be taken when inserting device in patients with severe peripheral arterial disease. Other relative contraindications and complications associated with device use are summarised in Table 2.

**The impella**

The Impella device (Abiomed, Danvers, Massachusetts) is catheter based miniaturised rotatory blood pump, usually inserted percutaneously through a 13–14 French sheath, with larger devices implanted via a surgical cut down. Given the size of the device, careful planning is required to ensure that the peripheral vessels are of adequate calibre. Whilst it is typically inserted via the transfemoral route, the axillary and transcaval approaches have also been used. The device, mounted on a 9 Fr Pigtail, is advanced retrogradely to the left ventricular cavity and is placed across the aortic valve. The distal end of catheter is connected to a portable mobile console that displays true invasive pressure, revolutions per minute of the pump and guides the correct positioning of the device. The micro axial pump continuously aspirates blood from the LV and expels it into the ascending aorta at rates of 2.5–5 liters/min. This leads to a reduction in LV volume with a concomitant increase in mean aortic pressure. As a result, systemic perfusion is increased, LV wall stress is reduced, and the transmyocardial perfusion gradient (aortic diastolic pressure – LV diastolic pressure) is increased. The effect on coronary haemodynamics is less well understood, but the device does appear to increase coronary perfusion pressure. Unlike the IABP, the Impella is independent of LV function and does not require cardiac synchrony. The effect of the Impella device on all parameters of cardiac function are far greater than the IABP, and indeed these effects are enhanced with the larger devices. Three versions of the Impella device are currently available: the Impella LP 2.5 (2.5 L flow), the Impella CP (3.7 L flow),

### Table 1. Comparison of different mechanical support devices.

| Mechanism | IABP | IMPELLA | Tandem Heart | VA ECMO |
| --- | --- | --- | --- | --- |
| Principle | Pneumatic (pressure counterpulsation) | Axial flow | Centrifugal flow | Centrifugal flow |
| Cardiac synchrony | Yes | No | No | No |
| **Haemodynamics** | | | | |
| Flow rate | 0.3–0.5L/min | 1–5L/min | 2.5–5 L/min | 3–7L/min |
| Cardiac power output | ↑ | ↑↑ | ↑↑ | ↑↑ |
| LV preload | ↓ | ↓ | ↓ | ↓ |
| LVEDP | ↓ | ↓ | ↓ | ↓ |
| Afterload | ↑ | ↑ | ↑ | ↑ |
| PCWP | ↓ | ↓ | ↓ | ↓ |
| Coronary perfusion | ↑ | ↑ | ↑ | ↑ |
| Myocardium O2 demand | ↓ | ↓ | ↓ | ↓ |
| TPR | ↓ | ↓ | ↓ | ↓ |
| Haemodynamic support | + | ++ | +++ | +++ |
| **Procedural aspects** | | | | |
| Sheath size | 7–8 Fr | 13–14 Fr, Impella 5.0–21 Fr | 15–17 Fr Arterial, Impella 21 Fr Venous | 14–16 Fr Arterial, Impella 18-21 Fr Venous |
| Implantation time | Short | Short - Medium | Long | Medium |
| Maximum no. of implant days | >7 Days | 7 Days | 14 Days | Weeks |
| Closure | Percutaneous | Percutaneous/ Surgical | Surgical | Surgical |
| Cost | £400-600 | £6600–15000 | £90,000b | £10,000 |

IABP: intra aortic balloon pump; VA ECMO: venoarterial extracorporeal membrane oxygenation; LV: left ventricle; LVEDP: left ventricle end diastolic pressure; PCWP: pulmonary capillary wedge pressure; O2: oxygen; TPR: total peripheral resistance; Fr: French; L/min liters/min.

aImpella is dependent on preload for effective action? = Unknown (Reference: 57).

bIncremental cost effectiveness ratio (ICER).
both of which can be implanted percutaneously, and the Impella LP 5 (5 L flow) which requires a surgical cut down. Despite increased operator experience and improvement in technology, device related haemolysis, bleeding and vascular complication rate remain high in recent registries and potentially blunt the haemodynamic gains from the device. A careful assessment of the peripheral vasculature is recommended to minimise the vascular complication risk, and implantation should ideally be ultrasound guided. Haemostasis at the arteriotomy site is routinely achieved with vascular closure devices (VCD). Absolute contraindications to device use include LV thrombus, severe aortic regurgitation and contraindication to use of anticoagulation.

More recently, an Impella device has been developed for right ventricular failure. The RP is a 22 Fr catheter based microaxial pump available for refractory right ventricular (RV) failure and is inserted via a femoral vein percutaneously; pump inflow is placed in inferior vena cava and outflow in pulmonary artery. The device can achieve an augmented forward flow of >4 L/min in pulmonary artery, reducing RV load and thereby increasing cardiac index. The safety and efficacy of device has been reported in very small series to date, demonstrating improved haemodynamics in patients with refractory right ventricular failure. In acute biventricular failure Impella 2.5/5.0/CP and Impella RP can be used together- Bipella, to provide haemodynamic support, facilitate LV/RV unloading and augment coronary and systemic perfusion.

The tandem heart

The Tandem Heart is an extracorporeal, centrifugal continuous flow device that can be used for left, right or biventricular failure. A 21 Fr transseptal cannula withdraws oxygenated blood from left atrium (LA) and is pumped back to iliofemoral arterial system using a 15 Fr–19 Fr arterial cannula using a centrifugal pump, thereby bypassing the LV. The pump can provide flows of 2.5–5 L/min.

By aspirating blood from LA, the system significantly reduces LV preload, filling pressures, and myocardial oxygen demand, whilst cardiac output and mean arterial pressure are augmented as blood is propelled back into arterial system. If retrograde flow from device exceeds forward flow from the LV this can result in aortic valve closure and there is a theoretical need to ‘vent’ the left ventricle. Anticoagulation is required with an activated clotting time (ACT) of 250–300 seconds recommended prior to device activation.

The size of the device, and the need for a transseptal puncture has limited its use. A major drawback remains the high incidence of vascular complications, device migration and cardiac tamponade. In a small randomised trial, Thiele et al. compared the use of the Tandem Heart with the IABP in patients with cardiogenic shock. Although clearly underpowered, no difference in outcome was seen between the two groups, but a much higher rate of major vascular complications and need for blood transfusion was associated with Tandem Heart.

The device has limited availability in National Health Service (NHS) and has a high estimated incremental cost effectiveness ratio (ICER) at £90,000 (Table 1).

Venoarterial extra corporeal membrane oxygenation (VA ECMO)

VA ECMO is a form of heart-lung bypass which offers temporary mechanical support and simultaneous
extracorporeal gas exchange in patients with refractory cardiogenic shock, usually acting as a bridge to recovery or destination therapies. It has been used widely since its introduction in 1972. VA ECMO can be implanted via a surgical cut-down in the operating theatre via sternotomy, surgical cannulation of right atrium and aorta- Central ECMO but is more routinely implanted percutaneously via a transfemoral/trans axillary approach- Peripheral ECMO. An 18–21 Fr cannula is inserted via femoral vein to right atrium and deoxygenated venous blood is withdrawn. The blood is then pumped through a membrane oxygenator in an extracorporeal centrifugal pump, oxygenated blood is returned to femoral artery through a 14–16 Fr reinfusion cannula. VA ECMO results in a dramatic increase in cardiac output and mean arterial pressure (Figure 1) and will usually achieve an increased flow rate of 4–6 L/minute.

Peripheral ECMO is a retrograde arterial system and can dramatically increase afterload leading to a higher LVEDP and increased myocardial oxygen demand. In CS setting if afterload generated by ECMO exceeds LVEDP, an already depressed LV cannot generate enough power to unload and the aortic valve remains closed for entire cardiac cycle which leads to LV distension, further increasing LVEDP and pulmonary capillary wedge pressure (PCWP) precipitating pulmonary oedema and acute lung injury. Further, stagnant blood is a nidus for thrombus formation in the LV cavity and aortic root with the consequent risk of thromboembolic complications.

The risk of LV distension with ECMO can be mitigated by venting the LV, either by increasing forward flow with use of inotropes/Impella, decreasing afterload by placement of an IABP, or direct decompression with an atrial septostomy. This can also be facilitated by decreasing intravascular volume with haemodialysis/diuretics or reducing the flow rate.31,32

There has been a significant improvement in device technology and increased operator experience, however the technology is still associated with a risk of significant complications, particularly related to the vascular access site- specially limb ischaemia associated with peripheral ECMO which can be mitigated with a reperfusion circuit established distal to the main arterial access site to maintain distal limb perfusion. Bleeding and haemolysis are also higher compared to other MCS due to blood loss in device, acquired von Willebrand syndrome, thrombocytopenia, and fragmentation of red cells due to high shear stress and mechanical strain (Table 2).7,17,33

**Mechanical circulatory support in cardiogenic shock**

Cardiogenic shock is defined by a combination of persistent hypotension (systolic blood pressure <80–90 mm Hg or mean arterial pressure 30 mm Hg lower than baseline), cardiac index (CI) <1.8 L/min/m² without support or <2.0–2.2 L/min/m² with support, elevated filling pressures (LVEDP > 18 mm Hg or RVEDP > 10–15 mmHg), as well as clinical signs/symptoms of hypoperfusion (cool extremities, decreased urine output, high lactate or altered mental status).5 CS complicates 6% to 8% of patients with acute myocardial infarction (AMI). Despite advances in PCI technique, availability of MCS and improved supportive care, the mortality of CS has remained static over the past 20 years.34,35 Whilst early and appropriate revascularisation of the culprit vessel in this setting improves survival, the evidence for mechanical support is much more limited.34–37

Clearly CS leads to reduced myocardial contractility and stroke volume, with concomitant increase in LVEDV, LVEDP and myocardial oxygen demand. Though there are clear theoretical benefits associated with the use of MCS devices in CS and often impressive effects on haemodynamic parameters, no study to date has shown that the use of MCS leads to an improvement in clinical outcome.29,38–41 This is a difficult patient population to include in randomised trials, for obvious reasons, and numerous questions remain regarding the timing of mechanical support, in particular whether this should take place before, during or after revascularisation, the intensity of other supportive therapies and patient selection.

The IABP is the most widely studied device in patients presenting with cardiogenic shock, which is not surprising given the ease of use, widespread availability and low cost. An early non-randomised study suggested improved survival with IABP use in 90 patients treated at two centres.42 The TACTICS study was a small single centre randomised trial which compared use of IABP in AMI with standard therapy. The study recruited only 47 patients, was therefore distinctly underpowered, and showed no difference in outcome between the two groups at 6 months.

Despite the limited data the routine use of IABP was encouraged by international guidelines receiving a Class I recommendation for much of the past 3 decades. Indeed, in the SHOCK study almost 90% of patients received an IABP whether or not they received urgent revascularisation.44

The IABP SHOCK I was a small sample randomised trial that investigated haemodynamic benefit and survival improvement with use of IABP in addition to PCI in CS complicating AMI. Although there was an initial improvement in haemodynamic parameters, beneficial effects were not sustained after 24 hours.43 The IABP in Cardiogenic Shock (IABP SHOCK- II) is the only large-scale randomised trial examining the use of an MCS in AMI. In this study 600 patients with
CS complicating AMI were randomised to IABP versus no IABP, with 80% of included patients receiving the device after PCI. 10% of the control group had IABP implantation within the first 24 hours. There was no difference in mortality between the two groups at 30 days, and this was sustained at 5 year follow up, in both the intention to treat, and as-treated cohorts.\(^44,45\) Importantly, there was no major difference in heart rate or blood pressure between the two groups, and indirect markers of end-organ perfusion such as serum lactate and renal function did not differ. Placement of the IABP before revascularisation had no apparent effect, although the numbers were too small to draw firm conclusions. There are numerous possible reasons why the IABP SHOCK II study was neutral. Augmentation of CO to maintain end organ perfusion was minimal and residual ischaemia from untreated bystander coronary artery disease may have affected long term outcomes.

Given the difficulties in performing randomised trials in this patient cohort, observational data is of interest. Several early registries suggested a mortality benefit of the IABP use following thrombolysis in CS complicating AMI\(^36,47\) however this has not been seen in metanalyses from the PCI era.\(^48\)–\(^50\)

The results from the IABP-SHOCK II study have had an inevitable impact on clinical guideline recommendations. The routine use of the IABP in CS has been downgraded from Class I to a Class III (not recommended) in the European guidelines.\(^51\) The change in guidelines has led to a concomitant reduction in IABP use across the US and Europe, as evidenced by several recent registries.\(^2\)

Other MCS devices have been less widely studied in both CS and high-risk PCI. The Impella device was the focus of one small, randomised multicentre study, the IMPRESS trial. 48 mechanically ventilated patients with CS were randomised 1:1 to IABP or the Impella device. 30 day and 6-month mortality were identical between the two groups (50% Impella vs 46% IABP) but the trial was not powered for any meaningful clinical end-points.\(^51\) As expected, the more powerful device delivered an impressive increase in haemodynamic parameters, with amelioration of mean arterial pressure, a reduction in ionotropic requirements and lower lactate in the first 24 hours; however there were more bleeding event in Impella cohort. There are a number of limitations of this study, not least the small numbers recruited. The less powerful 2.5L LP device was used, randomisation occurred after revascularisation, and a larger number in the Impella group received the device upfront 21 vs 13% in IABP group.\(^41\)

Seyfarth et al. in the ISAR Shock trial explored safety and haemodynamic effect of Impella LP 2.5 compared to IABP in patients with CS complicating AMI.\(^40\) There was an increase in Cardiac index in the Impella group and early reversal of serum lactate levels within 30 min of device implantation, however the Impella group required more blood transfusion. There are several limitations to the study, it was not adequately powered for clinical endpoints. CI was measured for a short period of time and device was implanted post revascularisation.\(^52\)

Karatolios et al. examined the use of the Impella in a single centre, retrospective cohort including only 20 patients.\(^53\) In this study the Impella group had a more prolonged low flow time period, higher serum lactate and worse LV function on admission. The device was associated with improved survival at discharge and 6 months after propensity score matching.\(^53\)

Schrage et al. matched 237 patients from IABP SHOCK II trial with 237 treated with Impella LP 2.5/CP for CS complicating AMI from EUROSHOCK registry and found no reduction in 30 day mortality with Impella use compared to IABP/standard medical therapy.\(^54\)

A subsequent meta-analysis showed a higher vascular and bleeding complications with no difference in outcome with Impella use.\(^55\)

Thiele et al. compared IABP with percutaneous LV assist device (Tandem Heart) in patients with CS complicating AMI. 41 patients, all mechanically ventilated were randomly assigned (1:1) , VAD Tandem heart significantly improved cardiac power index (CPI) and effectively lowered serum lactate compared to IABP, but was associated with a significantly higher rate of vascular and bleeding complications with no difference in 30-day mortality between groups (45% vs 43%).\(^29\)

Evidence for ECMO in CS is limited and data for clinical use is from non-randomised trials and large-scale registries. ECMO is associated with improved short term survival and favourable neurological outcome in patients with out of hospital cardiac arrest and CS complicating AMI.\(^56,57\)

**MCS during high risk PCI**

PCI has evolved significantly over the four decades since its development. Technological improvements include improved stent, balloon and delivery systems. Advanced imaging, adjunctive technology and a smorgasbord of complex interventional techniques have allowed the interventional cardiologist to deal with lesions of increasing complexity.

There are a number of factors which increase procedure complexity. Patient demographics such as advanced age, and baseline left ventricular function, must be considered in combination with the coronary anatomy in order to assess risk. The term ‘high risk PCI’ has been coined to encompass treatment for this patient group with complex coronary anatomy and poor LV systolic
function who have indications for coronary revascularisation, but are at high procedural risk.\textsuperscript{7,58} There is currently no uniform definition of high-risk PCI. However, there are a number of variables that potentially increase procedural complications and can be broadly grouped into the following: patient comorbidities/presentation, LV function/valvular disease and complexity of the coronary anatomy (Figure 2). In patients with a large ischaemic burden and poor LV systolic function, sustained hypotension with reduced coronary perfusion during PCI can lead to profound myocardial ischaemia, and further insult to an already impaired LV, with the potential to cause circulatory collapse and arrest.\textsuperscript{7}

MCS can theoretically prevent this spiral by providing haemodynamic stability throughout the procedure, increasing cardiac output to maintain myocardial and systemic perfusion, decrease myocardial oxygen demand and improve coronary perfusion.\textsuperscript{8}

However, despite the sound theoretical basis for the use of MCS during high risk PCI, there is a distinct paucity of evidence to support its use, with a limited number of randomised trials and observational studies.\textsuperscript{59,60}

The Balloon pump–assisted Coronary Intervention Study (BCIS-1) was a randomised, multi-center study which investigated whether elective use of IABP in high risk PCI reduced major adverse cardiovascular and cerebrovascular events (MACCE) at 28 days. 301 patients with severe LV impairment and severe coronary artery disease (BCIS -1 jeopardy score >8) were randomised to receive PCI with or without IABP (150). The elective use of the IABP use had no effect on MACCE at 28 days although baseline demographics were similar, and procedural success was >90%. There was a higher procedural complication rate in the ‘unplanned’ IABP group (10.7% vs 1.3%, P < 0.001). The degree of revascularisation was similar in both groups. Interestingly, at 51 months follow up there was a 34% relative reduction in all-cause mortality in IABP group.\textsuperscript{61} This apparent benefit at long term follow up may be a chance finding, and little to support a mechanistic benefit for this difference between the groups.

The Intra-aortic Balloon Counterpulsation and Infarct size in patients with Acute Anterior Myocardial Infarction Without Shock (CRISP AMI) was a randomised, multicenter study which explored whether implantation of IABP prior to undertaking primary PCI in patients with anterior STEMI without CS reduces infarct size, measured by cardiac magnetic resonance imaging (CMR). The study did not show a reduction in MI size with IABP, although it was postulated that this may be due to the lengthy time to revascularisation (average >180 min), which could have nullified the protective effect of LV unloading.\textsuperscript{62}

A sub study of CRISP AMI showed a trend towards reduced mortality at 6 months with use of IABP in patients with a large MI (ST elevation > 15 mm at baseline) and persistent ischaemia (ST resolution <50% post revascularisation).\textsuperscript{63}

PROTECT II was a randomised, prospective, multicenter study which explored the use of the of Impella CP 2.5 L in a population of patients undergoing high risk PCI. The primary end point was major adverse events (MAEs) at discharge and 30 days. 452 patients with complex 3-vessel disease or unprotected left main coronary artery disease and severely depressed left ventricular function were randomised to receive the Impella or IABP. The 2.5 L Impella undoubtedly provided superior hemodynamic support in comparison with IABP but this was not associated with any difference in outcome at 30 days (35.1% vs 40.1%, P = 0.227). The study was discontinued early due to futility based on observed 30-day results of the first 327 patients and only 69% of the planned 654 patients were enrolled. A post hoc analysis suggested a marginal benefit of the Impella in the ‘as-treated’ population – at

**Figure 2.** High risk PCI characteristics.
Table 3. Randomised clinical trials with comparison of mechanical cardiac support devices.

| Trial                        | Patient Cohort                      | Device/ Devices Compared | Primary End Point                                                                                                                                                                                                 | Outcomes                                                                                                                                                                                                 |
|------------------------------|-------------------------------------|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| High risk PCI                |                                      |                          |                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                   |
| BCIS – I (2010)              | High risk PCI (N = 301)              | Elective IABP vs No planned IABP | MACCEs at hospital discharge or 28 days after index PCI                                                                                                                                                                                                 | No significant difference in MACCEs                                                                                                                                                                                                                             |
| CRISP AMI (2011)             | Anterior AMI without CS (N = 337)   | IABP                     | If IABP insertion prior to pPCI reduced MI size (% of LV mass on CMR)                                                                                                                                                                                                   | No reduction in infarct size with IABP                                                                                                                                                                                                                           |
| PROTECT II (2012)            | Nonemergency High risk PCI (N = 447) | Impella vs IABP          | If Impella 2.5 reduced MAEs compared to IABP at discharge or 30 day                                                                                                                                                                                                   | No significant difference in MAEs at 30 day. Impella 2.5 significantly increased cardiac power compared to IABP                                                                                                                                                     |
| Cardiogenic shock            |                                      |                          |                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                   |
| TACTICS (2005)               | CS complicating AMI (N = 57)        | IABP                     | All cause mortality at 6 months                                                                                                                                                                                                                                     | IABP for 48 hrs after thrombolysis did not reduce mortality. Trend towards reduced mortality with IABP in Killip Class III/IV at 6 months                                                                                                                                 |
| Thiele et al (2005)          | AMI and CS (N = 41)                  | Tandem heart vs IABP     | Improvement in CPI 2 hours after device implantation                                                                                                                                                                                                                 | CPI significantly incremented in Tandem Heart group. No difference in mortality at 30 day                                                                                                                                                                             |
| Burkhoff et al (2006)        | CS (61.9% had MI) (N = 42)           | Tandem Heart vs IABP     | Change in Haemodynamics (CI/MAP/PCWP)                                                                                                                                                                                                                               | Tandem Heart significantly augmented CI, MAP and decreased PCWP. No change in 30-day mortality.                                                                                                                                                                   |
| ISAR SHOCK (2008)            | CS complicating AMI (N = 25)         | Impella 2.5 vs IABP      | Change in CI from baseline to 30 min after device implantation                                                                                                                                                                                                     | Delta change in CI was significantly greater with Impella 2.5 than IABP. 30-day mortality similar                                                                                                                                                                |
| IABP SHOCK II (2012)         | Early revascularisation (PCI or CABG) in AMI complicated by CS (N = 600) | IABP                     | 30-day all cause mortality                                                                                                                                                                                                                                        | IABP before or immediately after revascularisation did not reduce mortality                                                                                                                                                                                     |
| IMPRESS (2017)               | CS complicating AMI (N = 48)         | Impella CP vs IABP       | If Impella CP reduced 30-day mortality compared to IABP                                                                                                                                                                                                              | No difference in mortality at 30 days and 6 months                                                                                                                                                                                                                 |

CS: cardiogenic shock; AMI: acute myocardial infarction; IABP: intra aortic balloon pump; CPI: cardiac power index; CI: cardiac index; MAP: mean arterial pressure; PCWP: pulmonary capillary wedge pressure; MACCEs: major adverse cardiovascular cerebrovascular events; CMR: cardiac magnetic resonance imaging; MAEs: major adverse events; pPCI: primary percutaneous coronary intervention.
90 days, there was trend towards lower MAE’s in the Impella group (40.6% vs 51.5%, \( P = 0.006 \)) and a signal for more complete revascularization. Furthermore, the rate of repeat revascularisation was lower in Impella group (3.6% vs 7.8%, \( P = 0.056 \)).

Europella and USpella were large scale registries that evaluated safety and feasibility of Impella 2.5 in high risk PCI and measured outcomes with Impella support prior to undertaking PCI in patient with CS complicating AMI. Impella was safe to use pre PCI and allowed more complete revascularisation and improved 30 day survival.\(^6\)

Ameloot et al. reported similar results when they retrospectively analysed 198 patients who had high risk PCI in their center – 35% had MCS implanted prior to PCI and 65% had PCI without MCS. There was improved in survival at 24 hours and 30 days in the Impella group, but clearly this study was non-randomised, and underpowered to detect meaningful differences between the two groups.\(^6\)

However, a recent observational study by Amin et al. showed despite a significant increment in volume of Impella device usage for high risk PCI in the last decade, it remains associated with higher rates of adverse events (death, bleeding and stroke).\(^6\)

Evidence for role VA ECMO in elective high-risk PCI is limited and stems largely from small registries and observational studies. The technology can provide sustained haemodynamic support, thereby allowing longer balloon inflation time period and more complete revascularisation at cost of higher vascular complications and need for more blood transfusion compared with other MCS.\(^6\)

**Guidelines**

From available body of literature, the evidence for use of MCS in CS and high-risk PCI is weak (Table 3). Despite this, the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI) have given a Class IIb recommendation for use of MCS in elective and acute settings as an adjunct to HR PCI, depending upon the hemodynamic condition of the patient, anticipated risk of circulatory compromise during the procedure, and the need for hemodynamic support after revascularization.\(^3\)

The European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) differ from their American counterparts and recommend the short-term use of MCS only in setting of CS complicating AMI after careful consideration of patient age, co morbidities, neurological outcome and long-term prognosis (Class IIb). It does not recommend use of IABP in CS (Class III).\(^20\)

**Conclusion**

There is now an array of MCS devices available which provide varying degrees of haemodynamic support during PCI. However, the theoretical benefit of haemodynamic support has not translated into improved clinical outcomes in any randomised clinical trial in patients with CS or those undergoing high risk PCI. Morbidity associated with vascular complications remains the ‘Achilles heel’ of all MCS devices, and the decision to use them should be based on benefit vs risk (haemodynamic gain vs vascular/bleeding complication) individualised to the patient by a ‘Heart Team’. The next generation of percutaneous MCS – Impella 5.5, Aortix and intravascular ventricular assist device (iVAS) have been developed to encourage mobility and reduce vascular complication rates.\(^7\)

In the setting of cardiogenic shock, the IABP is the only MCS device which has been studied in well-constructed trials powered for clinical endpoints. The IABP has a relatively modest effect on cardiac output and does not appear to provide sufficient haemodynamic support to affect outcome. The other MCS devices undoubtedly deliver far greater support but have been studied in only a small population of patients to date.

Of the other MCS devices, the Impella in the most widely used in CS, but less than a hundred patients have been included in randomised trials, and the data from observational studies and post commercial registries needs to be interpreted with caution. In the setting of high-risk PCI, the only randomised controlled trial (RCT) was negative and recent observational studies has shown more harm than benefit.

Numerous questions remain unanswered, not least the precise patients who may benefit from MCS use, and timing of implantation, with some feasibility studies suggesting that early (pre-PCI) use of the Impella may confer an advantage in CS. Furthermore, this population is more heterogeneous than previously thought, and the new SCAI classification of CS\(^72\) may inform the design of future studies, perhaps with a focus on those patients at the more severe end of the physiological spectrum, in whom the use of MCS may be of benefit. A similar stratification of patients undergoing high risk PCI may also provide more clarity and could help to develop a predictive risk score to guide management of patients with significant co-morbidities and poor LV function who require treatment of complex coronary anatomy.

Given the current body of evidence for use of MCS is conflicting, largely from small scale randomised trials and observational studies, there has been a resurgence of interest in the field of late particularly around the Impella including proposals for new randomised trials.
There are a number of ongoing studies which may help to bridge the evidence gap for MCS use, particularly in cardiogenic shock. The DanGer Shock is an adequately powered multicentre trial that will address whether MCS with Impella CP improves survival in CS.\textsuperscript{73} EUROSHOCK is a prospective multicentre trial exploring if early ECMO intervention in patients with AMI and CS reduces mortality compared to standard treatment. The Detroit cardiogenic shock initiative was a feasibility study, has shown a significant improvement in survival to discharge results with early use of the Impella, and the National Cardiogenic Shock Initiative (NCSI) is actively recruiting to hopefully validate these results.

There is clear potential for these, and other well-constructed studies, to translate the theoretical promise of mechanical circulatory into tangible clinical benefits for these complex patient populations.

Acknowledgements
None

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval
None.

Guarantor
None

Contributorship
None

ORCID iD
Ritesh Kanyal https://orcid.org/0000-0003-4079-2578

References
1. Lorusso R, Gelsomino S, Parise O, et al. Venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock in elderly patients: Trends in application and outcome from the extracorporeal life support organization (ELSO) registry. \textit{Ann Thorac Surg} 2017;104:62–69.
2. Backhaus T, Fach A, Schmucker J, et al. Management and predictors of outcome in unselected patients with cardiogenic shock complicating acute ST-segment elevation myocardial infarction: results from the Bremen STEMI registry. \textit{Clin Res Cardiol} 2018;107:371–379.
3. O’Neill WW, Schreiber T, Wohns DHW, et al. The current use of impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella registry. \textit{J Interv Cardiol} 2014;27:1–11.
4. Cohen M, Urban P, Christenson JT, et al. Intra-aortic balloon counterpulsation in US and non-US centres: results of the benchmark\textsuperscript{®} registry. \textit{Eur Heart J} 2003;24:1763–1770.
5. Mandawat A and Rao SV. Percutaneous mechanical circulatory support devices in cardiogenic shock. \textit{Circ Cardiovasc Interv} 2017;10:1–11.
6. Myat A, Patel N, Tehrani S, et al. Percutaneous circulatory assist devices for high-risk coronary intervention. \textit{JACC Cardiovasc Interv} 2015;8:229–44.
7. Atkinson TM, Ohman EM, O’Neill WW, et al. A practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention an interventional perspective. \textit{JACC Cardiovasc Interv} 2016;9:871–883.
8. Burkhoff D, Sayer G, Doshi D, et al. Hemodynamics of mechanical circulatory support. \textit{J Am Coll Cardiol} 2015;66:2663–2674.
9. Briceno N, Kapur NK and Perera D. Percutaneous mechanical circulatory support: current concepts and future directions. \textit{Heart} 2016;102:1494–1507.
10. Burkhoff D and Naidu SS. The science behind percutaneous hemodynamic support: a review and comparison of support strategies. \textit{Cathet Cardiovasc Intervent} 2012;80:816–829.
11. Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. \textit{J Am Coll Cardiol} 2004;44:340–348.
12. Patterson T, Perera D and Redwood SR. Intra-aortic balloon pump for high-risk percutaneous coronary intervention. \textit{Circ Cardiovasc Interv} 2014;7:712–720.
13. De Silva K, Lumley M, Kailey B, et al. Coronary and microvascular physiology during intra-aortic balloon counterpulsation. \textit{JACC Cardiovasc Interv} 2014;7:631–640.
14. Papaioannou TG and Stefanadis C. Basic principles of the intraaortic balloon pump and mechanisms affecting its performance. \textit{ASAIO J} 2005;51:296–300.
15. Majithia A, Jumean M, Shih H, et al. The hemodynamic effects of the MEGA Intra-Aortic balloon counterpulsation pump. \textit{J Hear Lung Transplant} 2013;32:S226.
16. Pucher PH, Cummings IG, Shipolini AR, et al. Is heparin needed for patients with an intra-aortic balloon pump? \textit{Interact cardiovasc thorac surg} 2012;15:136–139.
17. Subramaniam AV, Barsness GW, Vallabhajosyula S, et al. Complications of temporary percutaneous mechanical circulatory support for cardiogenic shock: an appraisal of contemporary literature. \textit{Cardiol Ther} 2019;8:211–228.
18. Cheney AE and McCabe JM. Alternative percutaneous access for large bore devices. \textit{Circ Cardiovasc Interv} 2019;12:1–10.
19. Alqarqaz M, Basir M, Alaswad K, et al. Effects of impella on coronary perfusion in patients with critical coronary artery stenosis. *Circ Cardiovasc Interv* 2018;11:1–8.

20. Remmelink M, Sjauw KD, Henries JPS, et al. Effects of mechanical left ventricular unloading by impella on left ventricular dynamics in high-risk and primary percutaneous coronary intervention patients. *Cathet Cardiovasc Intervent* 2010;75:187–194.

21. Briceno N, Khan SQ, Clapp B, et al. Does ‘real-world’ mechanical circulatory support match randomised controlled trials? The United Kingdom impella (Ukpella) registry. *Heart* 2020; 106 (Suppl 2):A1 – A118.: 1–2.

22. Ouweneel DM, de Brabander J, Karami M, et al. Real-life use of left ventricular circulatory support with impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. *Eur Hear J Acute Cardiovasc Care* 2019;8:338–349.

23. Dhuva SS, Ross JS, Mortazavi BJ, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-Hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. *JAMA - J Am Med Assoc* 2020;323:734–745.

24. Kaki A, Blank N, Alraies MC, et al. Access and closure management of large bore femoral arterial access. *J Interven Cardiol* 2018;31:969–977.

25. Anderson M, Morris DL, Tang D, et al. Outcomes of patients with right ventricular failure requiring short-term hemodynamic support with the Impella RP device. https://doi.org/10.1016/j.healun.2018.08.001

26. Kapur NK, Esposito ML, Bader Y, et al. Mechanical circulatory support devices for acute right ventricular failure. *Circulation* 2017;136:314–326.

27. Kuchibhotla S, Esposito ML, Breton C, et al. Acute biventricular mechanical circulatory support for cardiogenic shock. *J Am Heart Assoc* 2017;6:1–9.

28. Alli OO, Singh IM, Holmes DR, et al. Percutaneous left ventricular assist device with TandemHeart for high-risk percutaneous coronary intervention: the Mayo clinic experience. *Cathet Cardiovasc Intervent* 2012;80:728–734.

29. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. *Eur Heart J* 2005;26:1276–1283.

30. NHS. Evidence review: mechanical assist devices for circulatory support (destination therapy) in people with advanced heart failure 1 2017;1:1–63.

31. Cevasco M, Takayama H, Ando M, et al. Left ventricular distension and venting strategies for patients on venoarterial extracorporeal membrane oxygenation. *J Thorac Dis* 2019;11:1676–1683.

32. Guglin M, Zucker MJ, Bazan VM, et al. Venoarterial ECMO for adults: JACC scientific expert panel. *J Am Coll Cardiol* 2019;73:698–716.

33. Rihal CS, Naidu SS, Givertz MM, et al. American Heart Association (AHA), and American College of Cardiology (ACC) 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino America. *J Am Coll Cardiol* 2015;65:e7–26, e26.

34. England TN. Complicated by cardiogenic shock. 1999;341:625–634.

35. Thiele H, Akin I, Sandri M, et al. One-year outcomes after PCI strategies in cardiogenic shock. *N Engl J Med* 2018;379:1699–1710.

36. Miller L. Cardiogenic shock in acute myocardial infarction: the era of mechanical support. *J Am Coll Cardiol* 2016;67:1881–1884.

37. Masoudi FA, Poniarkis A, de Lemos JA, et al. Trends in U.S. Cardiovascular care: 2016 report from 4 ACC national cardiovascular data registries. Trends in US Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries. *J Am Coll Cardiol* 2017;69:1427–1450.

38. Magnus OE, Nanas J, Stomel RJ, et al. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS trial. *J Thromb Thrombolysis* 2005;19:33–39.

39. Burkhoff D, Cohen H, Brunckhorst, C et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. *Am Heart J* 2006;152:469.e1–469.e8.

40. Seyfàrth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. *J Am Coll Cardiol* 2008;52:1584–1588.

41. Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circulatory support versus Intra-Aortic balloon pump in cardiogenic shock after acute myocardial infarction. *J Am Coll Cardiol* 2017;69:278–287.

42. Waksman R, Weiss AT, Gotsman MS, et al. Intra-aortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction. *Eur Heart J* 1993;

43. Prondzinsky R, Unverzagt S, Russ M, et al. Hemodynamic effects of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP shock trial. *Shock* 2012;37:378–384.

44. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med*. IABP-SHOCK II Trial Investigators 2012;367:1287–1296.

45. Thiele H, Zeymer U, Thelenmann N, et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-Year outcome of the Randomized IABP-SHOCK II Trial. *Circulation* 2019;139:395–403.
46. Stone GW, Ohman EM, Miller MF, et al. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. *J Am Coll Cardiol* 2003;41:1940–1945.

47. Barron HV, Every NR, Parsons LS, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the national registry of myocardial infarction 2. *Am Heart J* 2001;141:933–939.

48. Ahmad Y, Sen S, Shun-Shin MJ, et al. Intra-aortic balloon pump therapy for acute myocardial infarction: a meta-analysis. *JAMA Intern Med* 2015;175:931–939.

49. Sjauw KD, Engström AE, Vis MM, et al. A systematic review and Meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? *Eur Heart J* 2008;30:459–468.

50. Anderson JL. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2013;127:362–425.

51. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J, ESC Scientific Document Group* 2018;39:119–177.

52. Basir MB, Schreiber TL, Grines CL, et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. *Am J Cardiol* 2017;119:845–851.

53. Karatolios K, Chatzis G, Markus B, et al. Impella support compared to medical treatment for post-cardiac arrest shock after out of hospital cardiac arrest. *Resuscitation* 2018;126:104–110.

54. Schrage B, Ibrahim K, Loehn T, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock: matched-pair IABP-shock II trial 30-day mortality analysis. *Circulation* 2019;139:1249–1258.

55. Wernly B, Seelmaier C, Leistner D, et al. Mechanical circulatory support with impella versus intra-aortic balloon pump or medical treatment in cardiogenic shock – a critical appraisal of current data. *Clin Res Cardiol* 2019;108:1249–1257.

56. Burrell AJC, Pellegrino VA, Wolfe R, et al. Long-term survival of adults with cardiogenic shock after venoarterial extracorporeal membrane oxygenation. *J Crit Care* 2015;30:949–956.

57. Ouweeem DL, Schotborgh JV, Limpens J, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. *Intensive Care Med* 2016;42:1922–1934.

58. Kirtane AJ, Doshi D, Leon MB, et al. Treatment of higher-risk patients with an indication for revascularization. *Circulation* 2016;134:422–431.

59. Sjauw KD, Konorza T, Erbel R, et al. Supported high-risk percutaneous coronary intervention with the impella 2.5 device. The Europella Registry. *J Am Coll Cardiol* 2009;54:2340–2344.

60. Dixon SR, Henriques JPS, Mauri L, et al. A prospective feasibility trial investigating the use of the impella 2.5 system in patients undergoing High-Risk percutaneous coronary intervention (the PROTECT I trial). initial U. S. Experience. *JACC Cardiovasc Interv* 2009;2:91–96.

61. Perera D, Stables R, Clayton T, et al. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. *Circulation* 2013;127:207–212.

62. Patel MR, Smalling RW, Thiele H, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. *JACC – J Am Med Assoc* 2011;306:1329–1337.

63. Van Nunen LX, Van ’T Veer M, Schampaert S, et al. Intra-aortic balloon counterpulsation reduces mortality in large anterior myocardial infarction complicated by persistent ischaemia: a CRISP-AMI substudy. *EuroIntervention* 2015;11:286–292.

64. O’Neill, William W, Kleiman, NS, et al. A prospective, randomized clinical trial of hemodynamic support with impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. *Circulation* 2012;126:1717–1727.

65. Ameeloot K, Bastos M, Daemen J, et al. New-generation mechanical circulatory support during high-risk PCI: a cross-sectional analysis. *EuroIntervention* 2019;15:427–433.

66. Amin AP, Sputers JA, Curtis JP, et al. The evolving landscape of impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. *Circulation* 2020;141;273–284.

67. Teirstein PS, Vogel RA, Dorros G, et al. Prophylactic versus standby cardiopulmonary support for high risk percutaneous transluminal coronary angioplasty. *J Am Coll Cardiol* 1993;21:590–596.

68. Pavvides GS, Hauser AM, Stack RK, et al. Effect of peripheral cardiopulmonary bypass on left ventricular size, afterload and myocardial function during elective supported coronary angioplasty. *J Am Coll Cardiol* 1991;18:499–505.

69. Schreiber TL, Kodali UR, O’Neill WW, et al. Comparison of acute results of prophylactic intraaortic balloon pumping with cardiopulmonary support for percutaneous transluminal coronary angioplasty (PTCA). *Cathet Cardiovasc Diagn* 1998;45:115–119.

70. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J* 2019;40:87–165.

71. Lindseth RO. The next wave of mechanical circulatory support devices. *Card Interv Today* 2002;9:9–15.

72. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American college of cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the societ. *Catheter Cardiovasc Interv* 2019;94:29–37.

73. Udesen NJ, Møller JE, Lindholm MG, et al. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. *Am Heart J* 2019;214:60–68.